APR 18, 2024 6:00 AM PDT

Harnessing biomarkers and algorithms in assessing the Risk of Malignancy in an Adnexal mass: the role of HE4/ROMA in clinical cases

Sponsored by: Abbott

Event Date & Time
Date: April 18, 2024
Time: 6:00 AM (PDT), 9:00 AM (EDT), 3:00 PM (CEST)
Ovarian Cancer is the 9th most common cancer in the world1, and Europe has the highest rates of ovarian cancer in the world2.
Although the cancer antigen 125 (CA 125) assay has been used for more than two decades to screen and monitor ovarian cancer, newer biomarkers and tools are available for patient management. Differentiating between benign and malignant ovarian masses is essential for creating a system for patient referrals.
The addition of human epididymis protein 4 (HE4) to CA-125 and the use of the Risk of Ovarian Malignancy Algorithm (ROMA) demonstrate the possibility of differentiating between benign and malignant adnexal masses in both pre- and post-menopausal groups3,4.
This presentation will highlight two case studies on how diagnostic tools can help improve the management of epithelial ovarian cancer and potentially impact the patient's journey.
Learning Objectives:
  • Gain a perspective of how serum biomarkers can aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer.
  • Understand the emerging utility of HE4 and ROMA as an aid in estimating the risk of epithelial ovarian cancer in pre and post-menopausal women presenting with an adnexal mass undergoing surgical intervention.
  • Gain a better understanding of the utility of biomarkers and ROMA algorithm in patients presenting with adnexal masses.



  1. https//gco.iarc.fr/tomorrow/en/dataviz/tables?types=0&sexes=2&mode=cancer&group_populations=1&multiple_populations=0&multiple_cancers=1&cancers=39&populations=900&years=2025 accessed 14th March, 2024
  2. https://eurohealth.ie/policy-brief-women-and-ovarian-cancer-in-the-eu-2018/ accessed 15th March, 2024
  3. Chawla S, e al. Evaluation of Human Epididymis Protein 4, Risk of Ovarian Malignancy Algorithm, and Risk of Malignancy Index Efficiency for Ameliorating Sensitivity and Specificity for Differentiating Benign from Malignant Adnexal Masses. J Lab Physicians 2023.
  4. Terlikowska KM, et al Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. J Ovarian Res. 2016 Jul 19;9(1):43.


Webinars will be available for unlimited on-demand viewing after live event.

You May Also Like
Loading Comments...